When

Saturday, October 26, 2024

6:15 AM-7:15 AM ET

WheRE

Live Stream

Live Stream

faculty
John M. Fahrenholz, MD
Assistant Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee
Lauren M. Madigan, MD
Assistant Professor of Dermatology
University of Utah
Practicing Clinician
University Medical Center and Huntsman Cancer Institute
Salt Lake City, Utah
Anton Rets, MD
Associate Professor of Pathology
University of Utah School of Medicine
Associate Director, Pathology Residency Program
Medical Director, Hematopathology and Immunohistochemistry Laboratory
ARUP Laboratories, Inc.
Salt Lake City, Utah

The Non-CME Corporate Forum content and views expressed therein do not necessarily reflect the views, policies or position of the American College of Allergy, Asthma & Immunology.

There is no registration fee for attending this Non-CME Corporate Forum; however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the meeting room early.

Prefer to participate in person? Register at ExchangeCME.com/SMBostonLive.

Target Audience

The design of this activity addresses the needs of clinical immunologists, allergists, dermatologists, and other attendees of ACAAI who manage patients with nonadvanced systemic mastocytosis (SM).

Program Overview

Nonadvanced systemic mastocytosis (SM) is a difficult disorder to diagnose and manage due to the wide variety of symptoms, anaphylactic triggers, and a complicated individualized treatment paradigm. Join us for this engaging Expert Roundtable™ to hear multidisciplinary insights related to the diagnosis and treatment strategies for nonadvanced SM.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the pathophysiology of nonadvanced SM, including the effects of driver mutations on MC activation and the rationale for new targeted therapies
  • Assess symptoms and analyze laboratory and genetic testing results to differentially diagnose nonadvanced SM and classify subtype
  • Discuss recent clinical trial evidence and regulatory status for new and emerging targeted treatment options, including selective tyrosine kinase inhibitors and their role in treating SM
  • Formulate individualized treatment plans reflecting clinical evidence for treatment efficacy and safety, patient-reported outcomes, and shared decision making

Americans With Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact us prior to the live event at info@exchangecme.com.

Fee Information & Refund/Cancellation Policy

There is no fee for this program.

Register Now

attend event
Related events
SEP
25
2025
BRIDGE SM - Eastern Region
1.00 CME

Building Bridges Between Treatment Centers and Community Practices

Reducing Knowledge Gaps in the Management of Systemic Mastocytosis

Time: 12:00 PM-1:00 PM ET
Venue: Live Webinar - Eastern Region
Location: Live Webinar - East
Faculty: Matthew P. Giannetti, MD
SEP
25
2025
BRIDGE SM - Central Region
1.00 CME

Building Bridges Between Treatment Centers and Community Practices

Reducing Knowledge Gaps in the Management of Systemic Mastocytosis

Time: 12:00 PM-1:00 PM CT
Venue: Live Webinar - Central Region
Location: Live Webinar - Central
Faculty: Thanai Pongdee, MD
SEP
25
2025
BRIDGE SM - Western/Southern Region
1.00 CME

Building Bridges Between Treatment Centers and Community Practices

Reducing Knowledge Gaps in the Management of Systemic Mastocytosis

Time: 12:00 PM-1:00 PM PT
Venue: Live Webinar - Western/Southern Region
Location: Live Webinar - West/South
Faculty: Prithviraj Bose, MD
available resources
meeting slides
linked resources
Suggested Reading
Expert Roundtable™

Managing Nonadvanced Systemic Mastocytosis

The Expert Roundtable Session